Health system readiness is essential for the successful implementation of innovative interventions, such as radioligand therapy. The US has a market-driven health system, meaning it has to be ready for approved innovative therapies as there will be demand from people who are eligible for these treatments. In addition, it is widely known that race, socioeconomic status, and geography impact a person’s experience with cancer care in the US. Through collaboration and proactive planning, healthcare actors can help to ensure equitable provision of innovative treatments.
The US policy action blueprint and situation analysis report provide essential information on the barriers and policy actions required to ensure a comprehensive integration of radioligand therapy within cancer care in the US.
The policy action blueprint presents 13 policy actions needed to improve integration and readiness for radioligand therapy. These steps, to be taken by specific actors across the health system, will improve the current integration of radioligand therapy and form an important foundation for all future indications.
The policy action blueprint is supported by the situation analysis report, a comprehensive summary of the current levels of integration and readiness of radioligand therapy. Looking specifically at neuroendocrine tumors, lymphoma, and prostate cancer, the situation analysis report defines readiness and integration in the US, identifies the key policy barriers and opportunities for policy action, and provides a clear argument for evidence-based policy change.
The international readiness assessment framework was adapted and applied to the US context, leading to the development of a comprehensive policy-focused analysis of the current integration of radioligand therapy to inform health system planning. Five working papers were developed, with each one focusing on a key area of a health system: governance, regulation and reimbursement, identified need, service provision, and health information. Each paper provides a detailed analysis of the current level of integration of radioligand therapy within US cancer care specific to each domain. The findings were used to develop nationally specific, consensus-driven policy recommendations for key decision-makers to drive optimal system readiness for radioligand therapy.
The US radioligand therapy readiness assessment was led by The Health Policy Partnership, with support from Avalere Health and considerable input from a multidisciplinary US Expert Advisory Group. The group had full editorial control over the content of all materials, which reflect consensus among the group. All members provided their time for free. The outputs of this project are intended for educational purposes only and do not relate to any particular product. The project is supported through an unrestricted grant from Advanced Accelerator Applications, a Novartis Company, with additional support from Nordic Nanovector.